Rhumbline Advisers Buys 34,060 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Rhumbline Advisers grew its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 9.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 388,960 shares of the medical device company's stock after acquiring an additional 34,060 shares during the period. Rhumbline Advisers owned 0.19% of Cooper Companies worth $32,809,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Byrne Asset Management LLC acquired a new position in Cooper Companies during the fourth quarter valued at approximately $33,000. OFI Invest Asset Management bought a new stake in shares of Cooper Companies during the 4th quarter worth $34,000. New Age Alpha Advisors LLC acquired a new position in Cooper Companies in the 4th quarter valued at $38,000. Covestor Ltd grew its stake in Cooper Companies by 35.5% in the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company's stock valued at $42,000 after buying an additional 120 shares during the last quarter. Finally, Atala Financial Inc acquired a new position in Cooper Companies during the 4th quarter worth $51,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on COO. Robert W. Baird lowered their price target on Cooper Companies from $107.00 to $97.00 and set an "outperform" rating on the stock in a research report on Friday, May 30th. Wall Street Zen raised Cooper Companies from a "hold" rating to a "buy" rating in a report on Friday, May 30th. Stifel Nicolaus dropped their price target on Cooper Companies from $115.00 to $105.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. BNP Paribas raised Cooper Companies to a "hold" rating in a research report on Thursday, March 13th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and issued a $76.00 price objective (down previously from $110.00) on shares of Cooper Companies in a research note on Friday, May 30th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cooper Companies presently has a consensus rating of "Moderate Buy" and a consensus price target of $100.38.

Cooper Companies Trading Up 1.6%

NASDAQ:COO traded up $1.15 during trading hours on Friday, hitting $72.33. The stock had a trading volume of 4,093,480 shares, compared to its average volume of 1,589,612. The Cooper Companies, Inc. has a one year low of $65.00 and a one year high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The company has a market cap of $14.46 billion, a price-to-earnings ratio of 37.09, a P/E/G ratio of 2.25 and a beta of 0.98. The business's 50 day moving average is $78.53 and its 200-day moving average is $87.57.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings results on Thursday, May 29th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.03. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $995.12 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company's revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the business posted $0.85 EPS. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.